Septic shock after seasonal influenza vaccination in an HIV-infected patient during treatment with etanercept for rheumatoid arthritis: A case report

Clinical and Vaccine Immunology

Volumn 20, Issue 5, 2013, Pages 761-764

  De Nardo, Pasquale ^a   Bellagamba, Rita ^a   Corpolongo, Angela ^a   Gentilotti, Elisa ^a   Taglietti, Fabrizio ^a   Rosati, Silvia ^a   Galeazzi, Mauro ^c   Sebastiani, Gian Domenico ^b   Quinti, Isabella ^d   Nicastri, Emanuele ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CYCLOSPORIN A; DICLOFENAC; ECHINOCANDIN; EFAVIRENZ; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLUENZA VACCINE; LAMIVUDINE; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METHOTREXATE; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VANCOMYCIN; ZIDOVUDINE;

ACUTE KIDNEY FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC REACTION; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DISEASE EXACERBATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; FOLLOW UP; GLASGOW COMA SCALE; HEPATOSPLENOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN DEFICIENCY; INFLUENZA VACCINATION; LOADING DRUG DOSE; LUNG DISEASE; MULTIPLE ORGAN FAILURE; PARTIAL THROMBOPLASTIN TIME; PLASMAPHERESIS; PLEURA EFFUSION; POLYARTHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; RHEUMATOID ARTHRITIS; SEASONAL INFLUENZA; SEPTIC SHOCK; TREATMENT RESPONSE; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA VACCINES; MIDDLE AGED; MULTIPLE ORGAN FAILURE; RECEPTORS, TUMOR NECROSIS FACTOR; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 84876847450     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00081-13     Document Type: Article

References (24)

1. Walker UA, Tyndall A, Daikeler T. 2008. Rheumatic conditions in human immunodeficiency virus infection. Rheumatology (Oxford) 47:952-959. (Pubitemid 351865914)
2. Reveille JD, Williams FM. 2006. Infection and musculoskeletal conditions: rheumatologic complications of HIV infection. Best Pract. Res. Clin. Rheumatol. 20:1159-1179. (Pubitemid 44793726)
3. Bachmann F, Nast A, Sterry W, Philipp S. 2010. Safety and efficacy of the tumor necrosis factor antagonists. Semin. Cutan. Med. Surg. 29:35-47.
4. Kaur PP, Chan VC, Berney SN. 2007. Successful etanercept use in an HIV-positive patient with rheumatoid arthritis. J. Clin. Rheumatol. 13:79-80. (Pubitemid 46597670)
5. Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD. 2008. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann. Rheum. Dis. 67:710-712. (Pubitemid 351571938)
6. Galeazzi M, Giannitti C, Manganelli S, Benucci M, Scarpato S, Bazzani C, Caporali R, Sebastiani GD. 2008. Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmun. Rev. 8:100-103.
7. Mikhail M, Weinberg JM, Smith BL. 2008. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. Arch. Dermatol. 144:453-456. (Pubitemid 351581101)
8. Domm S, Cinatl J, Mrowietz U. 2008. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br. J. Dermatol. 159:1217- 1228.
9. Giannitti C, Benucci M, Caporali R, Manganelli S, Bellisai F, Sebastiani GD, Galeazzi M. 2009. Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection. Int. J. Immunopathol. Pharmacol. 22:543-546.
10. Giannitti C, Sebastiani GD, Manganelli S, Galeazzi M. 2011. Safety of anti-tumor necrosis factor agents in rheumatic potential carriers of occult hepatitis B virus. J. Rheumatol. 38:780-781.
11. Favalli EG, Desiati F, Atzeni F, Sarzi-Puttini P, Caporali R, Pallavicini FB, Gorla R, Filippini M, Marchesoni A. 2009. Serious infections during anti-TNF alpha treatment in rheumatoid arthritis patients. Autoimmun. Rev. 8:266-273.
12. Nuñez-Cornejo C, Borrás-Blasco J, Gracia-Perez A, Rosique-Robles JD, Lopez-Camps V, Casterã E, Abad FJ. 2008. Septic shock and community-acquired pneumonia associated with etanercept therapy. Int. J. Clin. Pharmacol. Ther. 46:193-197.
13. Zimmer C, Beiderlinden M, Peters J. 2006. Lethal acute respiratory distress syndrome during anti-TNF-alpha therapy for rheumatoid arthritis. Clin. Rheumatol. 25:430-432.
14. Maimon N, Brunton J, Chan AK, Marras TK. 2007. Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept. Thorax 62:739-740. (Pubitemid 47235021)
15. Aboulafia DM, Bundow D, Wilske K, Ochs UI. 2000. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin. Proc. 75:1093-1098.
16. Favero M, Raffeiner B, Cecchin D, Schiavon F. 2009. Septic arthritis caused by Rothia dentocariosa in a patient with rheumatoid arthritis receiving etanercept therapy. J. Rheumatol. 36:2846-2847.
17. Duchet-Niedziolka P, Launay O, Coutsinos Z, Ajana F, Arlet P, Barrou B, Beytout J, Bouchaud O, Brouqui P, Buzyn A, Chidiac C, Couderc LJ, Debord T, Dellamonica P, Dhote R, Duboust A, Durrbach A, Fain O, Fior R, Godeau B, Goujard C, Hachulla E, Marchou B, Mariette X, May T, Meyer O, Milpied N, Morlat P, Pouchot J, Tattevin P, Viard JP, Lortholary O, Hanslik T. 2009. Vaccination in adults with auto-immune disease and/or drug related immune deficiency: results of the GEVACCIM Delphi survey. Vaccine 27:1523-1529.
18. Rahier JF, Moutschen M, Van Gompel A, Van Ranst M, Louis E, Segaert S, Masson P, De Keyser F. 2010. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 49:1815-1827.
19. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ. 2010. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep. 59(RR-8):1-62.
20. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. 2007. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 46:608-611. (Pubitemid 46523304)
21. Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP. 2008. The effect of antitumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann. Rheum. Dis. 67:713-716. (Pubitemid 351571939)
22. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, Levartovsky D, Litinsky I, Kaufman I, Wigler I, Mendelson E, Elkayam O. 2006. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann. Rheum. Dis. 65:191-194. (Pubitemid 43131992)
23. Shoenfeld Y, Agmon-Levin N. 2011. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J. Autoimmun. 36:4-8.
24. De Keyser F. 2011. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr. Rheumatol. Rev. 7:77-87.